The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Cancer immunotherapy
Abstract
Cancer is the second leading cause of death in the industrialized world. Most cancer patients are treated by a combination of surgery, radiation and/or chemotherapy. Whereas the primary tumor can, in most cases, be efficiently treated by a combination of these standard therapies, preventing the metastatic spread of the disease through disseminated tumor cells is often not effective. The eradication of disseminated tumor cells present in the blood circulation and micro‐metastases in distant organs therefore represents another promising approach in cancer immunotherapy. Main strategies of cancer immunotherapy aim at exploiting the therapeutic potential of tumor‐specific antibodies and cellular immune effector mechanisms. Whereas passive antibody therapy relies on the repeated application of large quantities of tumor antigen‐specific antibodies, active immunotherapy aims at the generation of a tumor‐specific immune response combining both humoral and cytotoxic T cell effector mechanisms by the host's immune system following vaccination. In the first part of this review, concurrent developments in active and passive cancer immunotherapy are discussed. In the second part, the various approaches for the production of optimized monoclonal antibodies used for anti‐cancer vaccination are summarized.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Umaña, P., Jean–Mairet, J., Moudry, R., Amstutz, H., & Bailey, J. E. (1999) · Nature Biotechnology · doi:10.1038/6179 · Cited by 764
Wing, M. G., Moreau, T., Greenwood, J., Smith, R. M., Hale, G., Isaacs, J., Waldmann, H., Lachmann, P. J., & Compston, A. (1996) · Journal of Clinical Investigation · doi:10.1172/jci119110 · Cited by 257
High-level expression of recombinant IgG in the human cell line per.c6
Jones, D., Kroos, N., Anema, R., Van Montfort, B., Vooys, A., Kraats, S. V. D., Helm, E. V. D., Smits, S., Schouten, J., Brouwer, K., et al. (2003) · Biotechnology Progress · doi:10.1021/bp025574h · Cited by 158
Forecasting the cytokine storm following systemic interleukin (IL)-2 administration
Panelli, M. C., White, R., Foster, M., Martin, B., Wang, E., Smith, K., & Marincola, F. M. (2004) · Journal of Translational Medicine · doi:10.1186/1479-5876-2-17 · Cited by 139
Cited by
Oncolytic viruses in cancer therapy
Vähä-Koskela, M. J. V., Heikkilä, J. E., & Hinkkanen, A. E. (2007) · Cancer Letters · doi:10.1016/j.canlet.2007.02.002 · Cited by 333
Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma
Ferrucci, P. F., Pala, L., Conforti, F., & Cocorocchio, E. (2021) · Cancers · doi:10.3390/cancers13061383 · Cited by 317
Sambi, M., Bagheri, L., & Szewczuk, M. R. (2019) · Journal of Oncology · doi:10.1155/2019/4508794 · Cited by 313
Targeting dendritic cells with nano-particulate PLGA cancer vaccine formulations
Hamdy, S., Haddadi, A., Hung, R. W., & Lavasanifar, A. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.05.021 · Cited by 298
New insights regarding the regulation of chemotaxis by nucleotides, adenosine, and their receptors
Corriden, R., & Insel, P. A. (2012) · Purinergic Signalling · doi:10.1007/s11302-012-9311-x · Cited by 78
Metadata
- Authors
- Schuster, M., Nechansky, A., & Kircheis, R.
- Venue
- Biotechnology Journal
- Publisher
- Wiley
- Published
- 2006-02
- Volume
- 1
- Issue
- 2
- Pages
- 138-147
- ISSN
- 1860-6768 (ISSN-L)
- 1860-7314
- OpenAlex
- W4251112880
- Cited by
- 179
- References
- 4
- FWCI
- 1.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.